Cymbalta vs. Viibryd

See how Cymbalta and Viibryd compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Cymbalta is an SNRI approved for depression, anxiety, and several chronic pain conditions, while Viibryd is a SPARI approved only for major depressive disorder in adults.

  • Cymbalta's most common side effects are nausea and somnolence, while Viibryd's most common are diarrhea and nausea, and Viibryd must be taken with food to absorb properly.

  • Both drugs carry a boxed warning for suicidal thoughts in young people, but Viibryd carries added warnings for serotonin syndrome and angle-closure glaucoma risk.

Cymbalta vs. Viibryd Drug Summary

Cymbalta

Cymbalta (duloxetine) is a serotonin and norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder, generalized anxiety disorder, and several chronic pain conditions like diabetic neuropathy and fibromyalgia. It comes as a delayed-release capsule taken once or twice daily and has been available since 2004.

Viibryd

Viibryd (vilazodone) is a serotonin partial agonist and reuptake inhibitor (SPARI) approved only for major depressive disorder in adults. It is an oral tablet taken once daily with food, since food is needed for proper absorption, and has been available since 2011.

Cymbalta vs. Viibryd Side Effects

Cymbalta

Most common
nausea (up to 30%)
somnolence (up to 21%)
headache (up to 18%)
dizziness (up to 17%)

Viibryd

Most common
diarrhea (up to 28%)
nausea (up to 23%)
insomnia (6% to 7%)
vomiting (up to 5%)

Cymbalta vs. Viibryd Dosage

Cymbalta

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 30 mg once daily Week 1
Maximum dose 60 mg twice daily If needed
Dose changes 2 increases Every week

Viibryd

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily Days 1-7
Maximum dose 40 mg once daily Day 15 onward
Dose changes 2 increases Every 7 days

Cymbalta vs. Viibryd Indications

Cymbalta

Cymbalta treats depression and anxiety, but its unique advantage is FDA approval for chronic pain conditions like diabetic neuropathy, fibromyalgia, and musculoskeletal pain. This makes it a common choice when depression coexists with chronic pain.

  • Major depressive disorder (MDD)

  • Generalized anxiety disorder (GAD)

  • Diabetic peripheral neuropathic pain

Viibryd

Viibryd is approved only for major depressive disorder in adults, with no additional FDA-approved uses. It is not approved for pediatric depression, and clinicians sometimes use it off-label as an alternative to standard SSRIs.

  • Major depressive disorder (MDD) in adults

  • Not approved for pediatric MDD

  • No additional FDA-approved indications

Cymbalta vs. Viibryd Pros and Cons

Cymbalta

Cymbalta's broad approval for pain conditions plus depression makes it useful for patients with overlapping symptoms. It has been on the market since 2004 and is available as a lower-cost generic, but it requires caution in patients with liver or severe kidney disease.

Pros

  • Approved for chronic pain conditions like fibromyalgia and diabetic neuropathy

  • Available as a lower-cost generic, roughly $130 to $500 per month without insurance

  • Long track record, FDA-approved since 2004

  • Can be dosed once or twice daily for flexibility

Cons

  • Contraindicated in chronic liver disease and severe kidney impairment

  • Higher rates of nausea and somnolence than Viibryd

  • Can cause dry mouth and constipation more than Viibryd

  • May require twice-daily dosing at higher doses

Viibryd

Viibryd's distinct mechanism, partial serotonin receptor activity, may lower the risk of sexual side effects compared to older antidepressants. It has a simple once-daily schedule, but it must be taken with food and typically costs more since no generic is widely available.

Pros

  • Distinct mechanism (partial 5-HT1A agonism) may lower sexual side effects

  • Simple once-daily dosing with no dose increase beyond day 15

  • Lower rates of dry mouth and constipation than Cymbalta

  • Not associated with the somnolence risk seen with Cymbalta

Cons

  • Must be taken with food; absorption drops significantly without it

  • No widely available generic, typically $380 to $650 per month without insurance

  • Only approved for depression, not anxiety or pain conditions

  • Additional warnings for serotonin syndrome and angle-closure glaucoma

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.